ABSTRACT
Endometrial cancer (EC) is one of the most common gynecologic malignancies. The incidence of EC has markedly increased in recent years. EC is broadly classified into two groups [1]; type I ECs are linked to estrogen excess, hormone-receptor positivity, and favorable prognoses, whereas type II, primarily serous tumors, are more common in older women and have poorer outcomes [2]. Primary treatment, including surgery and radiation, cannot provide sufficient tumor control, especially in high-grade, undifferentiated tumors with deep muscle infiltration. Endocrine treatment, including medroxyprogesterone acetate or tamoxifen, is sometimes useful to improve the outcome. However, patients with type II EC and even some patients with type I EC are refractory to traditional endocrine treatment [3]. Thus, a new treatment is needed to achieve a better response.
